Navigation Links
Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
Date:4/1/2009

LONDON and SAN DIEGO, April 2, 2009 University College London Business PLC (UCLB) and Ocera Therapeutics Inc., a privately held biopharmaceutical company, announced the signing of an exclusive worldwide licensing agreement for UCL-L1V and all assets and technologies related to the compound for the treatment of acute hepatic encephalopathy (AHE).

The compound recently demonstrated that it directly reduces blood levels of ammonia, a highly toxic chemical that builds up during attacks of AHE.

Ocera will develop the licensed compound as its second pipeline compound and refer to it as OCR-002. OCR-002 is a novel injectable for the treatment of AHE in patients with advanced liver cirrhosis and acute liver failure.

The licensing agreement is based on research conducted by the collaborative global research project led by Professor Rajiv Jalan and the Liver Failure Group at the Institute of Hepatology, UCL (University College London). The research includes a study which demonstrated an acute and sustained reduction of systemic ammonia levels as well as decreased intracranial pressure in models of AHE in acute liver failure and cirrhosis. The data was published online in Hepatology in February 2009.

Clinical trials in patients with AHE due to cirrhosis and acute liver failure will be carried out at University College Hospital as well as other centres in 2009 under funding from the Medical Research Council (MRC) in the U.K. Ocera is planning to file an IND in late 2009 and U.S. trials will begin in early 2010.

AHE is a reversible neuropsychiatric abnormality frequently seen as a complication of acute liver failure and cirrhosis. With severe liver impairment, toxic substances such as ammonia that are normally removed by the liver accumulate in the blood and impair the function of brain cells.

Signs of AHE include impaired cognition, uncontrolled movements and decreased levels of consciousness leading to
'/>"/>

Contact: Ruth Metcalfe
r.metcalfe@gmail.com
44-020-767-99739
University College London
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award
2. Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis
3. A novel target for therapeutics against Staph infection
4. Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration
5. Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics
6. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
7. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
8. CU-Boulder, biotech firm team up on python project in search for human cardiac therapeutics
9. Michael J. Fox Foundation PD Therapeutics Conference
10. Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration
11. Syntermed licenses Emory ERTb software for enhanced cardiac imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2015)... , July 21, 2015 Today, ZTE ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... FPC1 02 5 for Axon , ...
(Date:7/13/2015)... 13, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced sampling of ClearPad ® ... integration (TDDI) product targeting smartphones and tablets. This ... Synaptics , best-in-class touch controller IP and ... developed in the company,s Japan Design Center. TDDI ...
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... Farrow and Zafer Iqbal, research professors at NJIT, were ... fabricating arrays of nanoscale electrical probes. Their discovery ... spatial variation of electrical activity inside biological cells. ... array technique that allows for an array of individual, ...
... Missouri officials announced today a $5 million grant agreement ... Translational Partnership Award Program. The goal of the partnership ... improve patient lives and suffering from any disease or ... will be used to support collaborative projects between biomedical ...
... assessment, written by WCS Senior Conservation Scientist Dr. John ... information on these species and how climate change ... region and from nearly 300 scientific papers. In ... through these remote roadless areas to evaluate their importance ...
Cached Biology News:Patent for arrays of nanoscale electrical probes awarded to NJIT today 2MU signs $5 million agreement with Coulter Translational Research Partnership Program 2MU signs $5 million agreement with Coulter Translational Research Partnership Program 3Where will grizzly bears roam? 2
(Date:7/29/2015)... -- Pfenex Inc. (NYSE MKT: PFNX) announced today that its ... Thursday, August 13, 2015, before the open of market.  ... a conference call to discuss the financial results and ... financial results and business update will be publicly distributed ... (US) or 1-412-542-4131 (international) and reference Pfenex to access ...
(Date:7/29/2015)... ... 2015 , ... The third Medical Innovation Impact Index (MI3) Alert considers FDA ... combinations. The current system received a score of 0 (range -10 to +10) for ... of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
(Date:7/29/2015)... Bruno, CA. (PRWEB) , ... July 29, 2015 ... ... agreement with PRC Clinical, a Silicon Valley-based CRO specializing in Clinical ... advisory services, and patient recruitment services. The core expertise of PRC Clinical is ...
Breaking Biology Technology:Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3
... new "gold standard" in the sensitivity of weighing scales. ... world,s first fully functional nanotube radio, researchers with Berkeley ... have fashioned a nanoelectromechanical system (NEMS) that can function ... of a single atom of gold. , Alex Zettl, ...
... Inc. (NYSE: MYL ),today announced that its ... the U.S. Food and Drug Administration (FDA),for its ... Tablets, 20 mg, 30 mg and 40 mg., ... of hypertension,are the generic version of Sciele Pharma,s ...
... Fred Alger Management, Inc. (Alger),a leading asset management ... as Vice President, Senior Analyst/Co-Portfolio Manager for,Alger covering ... industries., David received his Doctor of Medicine ... Chief Medical Resident. While in Pennsylvania David,served as ...
Cached Biology Technology:Golden scales 2Golden scales 3David Farhadi, M.D. to Join Alger as Vice President, Senior Analyst/Co-Portfolio Manager 2
... leading provider of X-ray crystallography services ... screening services to its pharmaceutical and ... binding of drug-like fragments to the ... targets, allowing scientists to develop novel, ...
...
... (AChE) activity. This is a highly sensitive, ... and easy to use assay for AChE ... A series of coupled enzyme reactions translates ... change in luminescence. Inhibitors of AChE are ...
Rabbit polyclonal to Vitronectin ( Abpromise for all tested applications). Antigen: Full length native Vitronectin (Cow) Entrez Gene ID: 7448 Swiss Protein ID: P04004...
Biology Products: